Scripps San Diego Genitourinary Annual Course in Oncology (GUACO) 2025

• Target Audience: oncologists, urologists, radiation oncologists, advanced practice providers
• Sample video: contact me for sample video
• Information:

SAN DIEGO GU Annual Course in Oncology (GUACO) Presented by Scripps Cancer Center

The San Diego Genitourinary Annual Course in Oncology (GUACO) promises to be a premier event for clinicians and practitioners who care for patients suffering from genitourinary malignancies. The focus of this course will be on prostate, bladder, and kidney cancer. This dynamic course features expert-led sessions designed to provide attendees with an overview of standard-of-care treatment algorithms and options, as well as innovative strategies for patient care. Through interactive case-based discussions and engaging panel sessions, participants will have the opportunity to deepen their understanding of complex

Educational Objectives

After attending this live activity, participants should be able to:

Summarize the current landscape of prostate, bladder, and kidney cancer, highlighting epidemiological trends, advancements in diagnosis, treatment strategies, and ongoing challenges in patient management.

Explore current best practices and emerging approaches in the management of localized and advanced genitourinary malignancies, focusing on evidence-based standards and innovative strategies shaping the future of GU cancer care.

Develop a comprehensive outline of optimal clinical approaches for utilizing available treatment modalities in the management of GU malignancy.

Integrate multidisciplinary collaboration and shared decision-making into the management of complex patient cases, emphasizing coordinated care and proactive strategies to mitigate unfavorable clinical outcomes.

The Scripps San Diego Genitourinary Annual Course in Oncology (GUACO) 2025 is best for oncologists, urologists, radiation oncologists, advanced practice providers, and trainees who want CME‑accredited, expert‑led updates on the latest therapies, clinical trials, and multidisciplinary management of genitourinary cancers.

Who Should Attend

Medical oncologists and hematologists treating prostate, bladder, kidney, and testicular cancers.

Urologists and surgical oncologists involved in surgical management of GU malignancies.

Advanced practice providers (NPs, PAs, CNSs) working in oncology or urology clinics.

Residents and fellows in oncology, urology, or radiation oncology preparing for subspecialty practice.

Oncology nurses and pharmacists supporting GU cancer treatment and survivorship care.

What You’ll Learn

Latest clinical trial data and FDA approvals in GU oncology.

Updates in systemic therapies: immunotherapy, targeted therapy, and hormonal therapy for prostate and bladder cancer.

Surgical and radiation advances: minimally invasive techniques, focal therapy, and integration with systemic treatment.

Multidisciplinary case discussions: real‑world scenarios highlighting diagnostic and therapeutic challenges.

Survivorship and supportive care strategies tailored to GU cancer patients.

• Topics:

Friday, September 12, 2025

4 p.m. Registration & Welcome Reception

5 p.m. Keynote Presentation New Frontiers in Molecular Imaging of Kidney Cancer Brian Shuch, MD

Saturday, September 13, 2025

7:30 a.m. Breakfast & View Exhibits

8:25 a.m. Welcome & Educational Overview Ramdev Konijeti, MD

Session I: Prostate Cancer 8:30 a.m. Prostate Cancer Screening and Detection in 2025 Ramdev Konijeti, MD

8:45 a.m. Role of Primary Therapy in Oligometastatic Prostate Cancer Shane Mesko, MD

9 a.m. Prostate Cancer Theranostics: Current and Future Nik Patel, MD

9:15 a.m. Castrate Resistant Prostate Cancer in 2025 Mohammad Jaloudi, MD

9:30 a.m. Case Presentations/Panel Discussion 10 a.m. Break & View Exhibits

Session II: Bladder Cancer 10:30 a.m. Intravesical Therapy and Management of Non-Muscle Invasive Bladder Cancer Ramdev Konijeti, MD

11 a.m. Role of Lymphadenectomy in 2025 Phil Kim, MD

11:15 a.m. Immunotherapy and Antibody Drug Conjugates—Future of Systemic Therapy in Bladder Cancer Munveer Bhangoo, MD

11:30 a.m. Case Presentations/Panel Discussion Noon Lunch

Session III: Kidney Cancer 1:15 p.m. Radiotherapy for Small Renal Masses Patrick Linson, MD

1:30 p.m. Cytoreductive Nephrectomy in 2025 Carol Salem, MD

1:45 p.m. Subtyping Renal Cell Carcinoma Phataraporn Thorson, MD

2 p.m. Hereditary Kidney Cancer Guidelines 2025 Brian Shuch, MD

2:15 p.m. Case Presentations/Panel Discussion

2:45 p.m. Adjourn Topics, times and speakers are subject to change